PRESS-RELEASE filed May 5, 2026 at 06:45 ET
BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted EPS -€2.10), which beat the consensus EPS estimate of -$1.92 by ~35%. The company reaffirmed full-year 2026 revenue guidance of €2.0B-€2.3B and announced a planned $1B share repurchase program and a major manufacturing footprint consolidation expected to yield ~€500M in annual savings by 2029. However, the core COVID-19 vaccine business continues to decline, and the oncology pipeline, while advancing with multiple pivotal trial initiations, remains pre-commercial.